Moreover, TMPRSS2 could be a viable drug target in COVID-19 patients, and camostat mesilate, or other novel TMPRSS2 inhibitors, may have a role in the treatment of COVID-19. This evidence concerns the gene TMPRSS2 and COVID-19.